

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Forty-ninth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

An annual subscription to this series, comprising about four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int; order online: <http://www.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
9 9 2

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Forty-ninth report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Forty-ninth report of the WHO Expert Committee on specifications for pharmaceutical preparations.

(WHO technical report series ; no. 992)

1. Pharmaceutical Preparations - standards. 2. Technology, Pharmaceutical - standards.
3. Drug Industry - legislation. 4. Quality Control.
I. World Health Organization. II. Series.

ISBN 978 92 4 120992 2

(NLM classification: QV 771)

ISBN 978 92 4 069396 8 (PDF)

ISSN 0512-3054

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Contents

WHO Expert Committee on Specifications for Pharmaceutical Preparations	vi
1. Introduction	1
2. General policy	3
2.1 International collaboration	3
2.1.1 Collaboration with international organizations and agencies	3
2.2 Cross-cutting pharmaceutical quality assurance issues	6
3. Quality control – specifications and tests	8
3.1 <i>The International Pharmacopoeia</i>	8
3.1.1 Workplan for <i>The International Pharmacopoeia</i>	8
3.2 Specifications for medicines, including paediatric medicines and radiopharmaceuticals	9
3.2.1 Maternal, newborn, child and adolescent health medicines	9
3.2.2 Antiviral medicines, including antiretrovirals	11
3.2.3 Antituberculosis medicines	11
3.2.4 Medicines for tropical diseases	11
3.2.5 Other anti-infective medicines	13
3.2.6 Medicines for anaesthesia, pain and palliative care	13
3.2.7 Radiopharmaceuticals	14
3.3 General monographs for dosage forms and associated method texts	15
3.3.1 General monographs	15
3.3.2 General policy	16
3.3.3 Analytical methods	17
3.4 Update on the process for development of monographs	17
3.4.1 General	17
3.4.2 Radiopharmaceuticals	18
4. Quality control – international reference materials (International Chemical Reference Substances and Infrared Reference Spectra)	19
4.1 Update on International Chemical Reference Substances	19
4.1.1 Report of the custodian centre	19
4.1.2 Report of the dedicated subgroup	19
5. Quality control – national laboratories	20
5.1 External Quality Assurance Assessment Scheme	20
5.1.1 Summary report on External Quality Assurance Assessment Scheme Phase 5	20
5.2 Training materials for quality control laboratories and microbiological laboratories	21
5.3 Report on implementation of WHO good practices for pharmaceutical control laboratories	21
6. Quality assurance – good manufacturing practices	22
6.1 Update of WHO good manufacturing practices for biologicals	22
6.2 Update of WHO good manufacturing practices: validation	22
6.2.1 Proposal for revision of the supplementary guidelines on good manufacturing practices: validation, Appendix 7: non-sterile process validation	22

6.3	General guidance for inspectors on hold-time studies	23
6.4	Update of model inspection report	23
6.5	Update of questions and answers for WHO good manufacturing practices for active pharmaceutical ingredients	24
6.6	Proposal for new guidance on good data management	24
6.7	Training materials	25
7.	Quality assurance – new initiatives	26
7.1	International meetings of world pharmacopoeias	26
7.2	Good pharmacopoeial practices	26
7.3	Screening technologies for “suspect” spurious/falsely-labelled/falsified/counterfeit medicines	27
7.4	Laboratory functions survey regarding testing of spurious/falsely-labelled/falsified/counterfeit medical products	28
7.5	FIP–WHO technical guidelines: points to consider in the provision by health-care professionals of children-specific preparations that are not available as authorized products	29
7.6	Sampling procedures for market surveillance	29
7.6.1	Sampling procedures for spurious/falsely-labelled/falsified/counterfeit medical products	30
8.	Quality assurance – distribution and trade of pharmaceuticals	31
8.1	WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce	31
8.2	Monitoring and surveillance of the national supply chain	31
8.3	Technical supplement materials to the WHO guidance for storage and transport of time- and temperature-sensitive pharmaceutical products	32
9.	Prequalification of priority essential medicines	35
9.1	Update on the Prequalification Team managed by WHO	35
9.2	Revision of the collaborative registration procedure for prequalification of products	36
10.	Prequalification of active pharmaceutical ingredients	37
10.1	Update on the prequalification of active pharmaceutical ingredients	37
11.	Prequalification of quality control laboratories	38
11.1	Update on the prequalification of quality control laboratories	38
11.2	Update on WHO quality monitoring projects	38
12.	Regulatory guidance	39
12.1	Recommendation for quality requirements – artemisinin starting materials	39
12.2	Guidelines on variations for multisource products	39
12.3	Guidelines on registration requirements to establish interchangeability (bioequivalence)	39
12.4	Guidance for organizations performing in vivo bioequivalence studies – revision	40
12.5	Update of Biowaiver list based on the WHO Model List of Essential Medicines	41
12.6	Update of International Comparator Products List and related guidance on selection of comparator products for equivalence assessment of interchangeable multisource (generic) products	41
12.7	Good review practice	42
12.8	Good regulatory practices project	43

13. Nomenclature, terminology and databases	45
13.1 Quality assurance terminology	45
13.2 International Nonproprietary Names for pharmaceutical substances	45
14. Miscellaneous	46
14.1 Strategy	46
14.2 Outreach	46
15. Summary and recommendations	47
Acknowledgements	53
Annex 1	
Procedure for the development of monographs and other texts for <i>The International Pharmacopoeia</i>	69
Annex 2	
Updating mechanism for the section on radiopharmaceuticals in <i>The International Pharmacopoeia</i>	73
Annex 3	
Guidelines on good manufacturing practices: validation, Appendix 7: non-sterile process validation	75
Annex 4	
General guidance on hold-time studies	87
Annex 5	
Technical supplements to Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products	95
Annex 6	
Recommendations for quality requirements when plant-derived artemisinin is used as a starting material in the production of antimalarial active pharmaceutical ingredients	123
Annex 7	
Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability	131
Annex 8	
Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products	185
Annex 9	
Good review practices: guidelines for national and regional regulatory authorities	191

WHO Expert Committee on Specifications for Pharmaceutical Preparations

Geneva, 13–17 October 2014

Members¹

Professor S.A. Bawazir, Advisor to the Chief Executive Officer, Saudi Food and Drug Authority, Riyadh, Saudi Arabia (*Co-Chairperson*)

Professor T.G. Dekker, Research Institute for Industrial Pharmacy, North-West University, Potchefstroom, South Africa

Ms M. Hirschhorn, Head, Quality and Chemistry Sector, Comisión para el Control de Calidad de Medicamentos, Montevideo, Uruguay

Professor J. Hoogmartens, Professor Emeritus, Laboratorium voor Farmaceutische Analyse, Leuven, Belgium

Professor S. Jin, Chief Expert for Pharmaceutical Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China

Professor H.G. Kristensen, Vedbaek, Denmark

Ms G.N. Mahlangu, Director-General, Medicines Control Authority of Zimbabwe, Harare, Zimbabwe (*Chairperson*)

Dr L. Stoppa, Inspections and Certification Department, Manufacturing Authorisation Office, Italian Medicines Agency, Rome, Italy (*Co-Rapporteur*)

Dr A.J. van Zyl, Cape Town, South Africa (*Co-Rapporteur*)

Temporary advisers²

Dr P. Aprea, Head, Biological Products Department, National Administration of Drugs, Food and Medical Technology (ANMAT), Ministry of Health, Ciudad Autonoma de Buenos Aires, Argentina

Dr A.C. Moreira, Maringá, Brazil, Brazilian Pharmacopoeia Coordinator, Brazilian Health

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>